Search

Your search keyword '"Kibler, Karen V."' showing total 9 results
Start Over Author "Kibler, Karen V." Publisher american society for microbiology
9 results on '"Kibler, Karen V."'

1. Correction for Kibler et al., “Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC”

Author

Kibler, Karen V., primary, Asbach, Benedikt, additional, Perdiguero, Beatriz, additional, García-Arriaza, Juan, additional, Yates, Nicole L., additional, Parks, Robert, additional, Stanfield-Oakley, Sherry, additional, Ferrari, Guido, additional, Montefiori, David C., additional, Tomaras, Georgia D., additional, Roederer, Mario, additional, Foulds, Kathryn E., additional, Forthal, Donald N., additional, Seaman, Michael S., additional, Self, Steve, additional, Gottardo, Raphael, additional, Phogat, Sanjay, additional, Tartaglia, James, additional, Barnett, Susan, additional, Cristillo, Anthony D., additional, Weiss, Deborah, additional, Galmin, Lindsey, additional, Ding, Song, additional, Heeney, Jonathan L., additional, Esteban, Mariano, additional, Wagner, Ralf, additional, Pantaleo, Giuseppe, additional, and Jacobs, Bertram L., additional

Published
2019
Full Text
View/download PDF

2. Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost

Author

Asbach, Benedikt, primary, Kibler, Karen V., additional, Köstler, Josef, additional, Perdiguero, Beatriz, additional, Yates, Nicole L., additional, Stanfield-Oakley, Sherry, additional, Tomaras, Georgia D., additional, Kao, Shing-Fen, additional, Foulds, Kathryn E., additional, Roederer, Mario, additional, Seaman, Michael S., additional, Montefiori, David C., additional, Parks, Robert, additional, Ferrari, Guido, additional, Forthal, Donald N., additional, Phogat, Sanjay, additional, Tartaglia, James, additional, Barnett, Susan W., additional, Self, Steven G., additional, Gottardo, Raphael, additional, Cristillo, Anthony D., additional, Weiss, Deborah E., additional, Galmin, Lindsey, additional, Ding, Song, additional, Heeney, Jonathan L., additional, Esteban, Mariano, additional, Jacobs, Bertram L., additional, Pantaleo, Giuseppe, additional, and Wagner, Ralf, additional

Published
2019
Full Text
View/download PDF

3. Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC

Author

Kibler, Karen V., primary, Asbach, Benedikt, additional, Perdiguero, Beatriz, additional, García-Arriaza, Juan, additional, Yates, Nicole L., additional, Parks, Robert, additional, Stanfield-Oakley, Sherry, additional, Ferrari, Guido, additional, Montefiori, David C., additional, Tomaras, Georgia D., additional, Roederer, Mario, additional, Foulds, Kathryn E., additional, Forthal, Donald N., additional, Seaman, Michael S., additional, Self, Steve, additional, Gottardo, Raphael, additional, Phogat, Sanjay, additional, Tartaglia, James, additional, Barnett, Susan, additional, Cristillo, Anthony D., additional, Weiss, Deborah, additional, Galmin, Lindsey, additional, Ding, Song, additional, Heeney, Jonathan L., additional, Esteban, Mariano, additional, Wagner, Ralf, additional, Pantaleo, Giuseppe, additional, and Jacobs, Bertram L., additional

Published
2019
Full Text
View/download PDF

4. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates

Author

García-Arriaza, Juan, primary, Perdiguero, Beatriz, additional, Heeney, Jonathan L., additional, Seaman, Michael S., additional, Montefiori, David C., additional, Yates, Nicole L., additional, Tomaras, Georgia D., additional, Ferrari, Guido, additional, Foulds, Kathryn E., additional, Roederer, Mario, additional, Self, Steven G., additional, Borate, Bhavesh, additional, Gottardo, Raphael, additional, Phogat, Sanjay, additional, Tartaglia, Jim, additional, Barnett, Susan W., additional, Burke, Brian, additional, Cristillo, Anthony D., additional, Weiss, Deborah E., additional, Lee, Carter, additional, Kibler, Karen V., additional, Jacobs, Bertram L., additional, Wagner, Ralf, additional, Ding, Song, additional, Pantaleo, Giuseppe, additional, and Esteban, Mariano, additional

Published
2017
Full Text
View/download PDF

5. Replication-competent NYVAC-KC yields improved immunogenicity to HIV-1 antigens in rhesus macaques, compared to non-replicating NYVAC.

Author

Kibler, Karen V., Asbach, Benedikt, Perdiguero, Beatriz, García-Arriaza, Juan, Yates, Nicole L., Parks, Robert, Stanfield-Oakley, Sherry, Ferrari, Guido, Montefiori, David C., Tomaras, Georgia D., Roederer, Mario, Foulds, Kathryn E., Forthal, Donald N., Seaman, Michael S., Self, Steve, Gottardo, Raphael, Phogat, Sanjay, Tartaglia, James, Barnett, Susan, and Cristillo, Anthony D.

Subjects
*RHESUS monkeys, *IMMUNOGENETICS, *HIV infections, *AIDS vaccines, *POXVIRUSES
Abstract

As part of the continuing effort to develop an effective HIV vaccine, we generated a poxviral vaccine vector (previously described) designed to improve on the results of the RV144 Phase III clinical trial. The construct, NYVAC-KC, is a replication-competent, attenuated recombinant of the vaccinia virus strain, NYVAC. NYVAC is a vector that has been used in many previous clinical studies but is replication deficient. Here we report a side-by-side comparison of replication-restricted NYVAC and replication-competent NYVAC-KC in a non-human primate study, which utilized a prime-boost regimen similar to that of RV144. NYVAC-C and NYVAC-C-KC express the HIV-1 antigens gp140 and Gag/Gag-Pol-Nef-derived VLPs from clade C and were used as the prime, with recombinant virus plus envelope protein as the boost. In nearly every T and B cell immune assay against HIV-1, including neutralization and antibody binding, NYVAC-C-KC induced a greater immune response than did NYVAC-C, indicating that replication competence in a poxvirus may improve upon the modestly successful regimen used in the RV144 clinical trial. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

7. Virological and Immunological Characterization of Novel NYVAC-Based HIV/AIDS Vaccine Candidates Expressing Clade C Trimeric Soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as Virus-Like Particles

Author

Perdiguero, Beatriz, primary, Gómez, Carmen Elena, additional, Cepeda, Victoria, additional, Sánchez-Sampedro, Lucas, additional, García-Arriaza, Juan, additional, Mejías-Pérez, Ernesto, additional, Jiménez, Victoria, additional, Sánchez, Cristina, additional, Sorzano, Carlos Óscar S., additional, Oliveros, Juan Carlos, additional, Delaloye, Julie, additional, Roger, Thierry, additional, Calandra, Thierry, additional, Asbach, Benedikt, additional, Wagner, Ralf, additional, Kibler, Karen V., additional, Jacobs, Bertram L., additional, Pantaleo, Giuseppe, additional, and Esteban, Mariano, additional

Published
2015
Full Text
View/download PDF

9. Virological and Immunological Characterization of Novel NYVAC-Based HIV/AIDS Vaccine Candidates Expressing Clade C Trimeric Soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as Virus-Like Particles.

Author

Gómez, Carmen Elena, Cepeda, Victoria, Sánchez-Sampedro, Lucas, García-Arriaza, Juan, Mejías-Pérez, Ernesto, Jiménez, Victoria, Sánchez, Cristina, Sorzano, Carlos Óscar S., Oliveros, Juan Carlos, Delaloye, Julie, Roger, Thierry, Calandra, Thierry, Asbach, Benedikt, Wagner, Ralf, Kibler, Karen V., Jacobs, Bertram L., Pantaleo, Giuseppe, and Esteban, Mariano

Subjects
*AIDS vaccination research, *HIV infections -- Immunological aspects, *VIRUS-like particles, *VIROLOGY -- Technique, *HIV seronegativity, *IMMUNITY
Abstract

The generation of vaccines against HIV/AIDS able to induce long-lasting protective immunity remains a major goal in the HIV field. The modest efficacy (31.2%) against HIV infection observed in the RV144 phase III clinical trial highlighted the need for further improvement of HIV vaccine candidates, formulation, and vaccine regimen. In this study, we have generated two novel NYVAC vectors, expressing HIV-1 clade C gp140(ZM96) (NYVAC-gp140) or Gag(ZM96)-Pol-Nef(CN54) (NYVAC-Gag-Pol-Nef), and defined their virological and immunological characteristics in cultured cells and in mice. The insertion of HIV genes does not affect the replication capacity of NYVAC recombinants in primary chicken embryo fibroblast cells, HIV sequences remain stable after multiple passages, and HIV antigens are correctly expressed and released from cells, with Env as a trimer (NYVAC-gp140), while in NYVAC-Gag-Pol-Nef-infected cells Gag-induced virus-like particles (VLPs) are abundant. Electron microscopy revealed that VLPs accumulated with time at the cell surface, with no interference with NYVAC morphogenesis. Both vectors trigger specific innate responses in human cells and show an attenuation profile in immunocompromised adult BALB/c and newborn CD1 mice after intracranial inoculation. Analysis of the immune responses elicited in mice after homologous NYVAC prime/NYVAC boost immunization shows that recombinant viruses induced polyfunctional Env-specific CD4 or Gag-specific CD8 T cell responses. Antibody responses against gp140 and p17/p24 were elicited. Our findings showed important insights into virus-host cell interactions of NYVAC vectors expressing HIV antigens, with the activation of specific immune parameters which will help to unravel potential correlates of protection against HIV in human clinical trials with these vectors. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results